ASCO 2024 preview – Merus’s home run remains unconfirmed
Petosemtamab meets sellside forecasts, but for the bull case you need to include an unconfirmed response.
ASCO 2024 preview – waiting for Blueprint and Caribou
Just-released abstracts leave investors hungry for details on BLU-222 and CB-010.
ASCO 2024 preview – new Car-T target shows liver cancer promise
Targeting GPC3 has scored a win for AstraZeneca’s Chinese partner, after Takeda drew a blank.
ASCO 2024 preview – two strikes against USP1
Tango cans TNG348 while Roche’s KSQ-4279 looks virtually inactive.
ASCO 2024 preview – jury still out on AbbVie's cancer push
SEZ6 looks promising but early, while questions remain around toxicity with AbbVie's cMet ADCs.
Agenus tries again with the FDA
A July meeting with the FDA could determine whether Agenus’s bot-bal combo has a shot at a 2024 filing.
